April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Culture of Rat Müller Cells in Alginate Capsules for Sustained Release of Brain-Derived Neurotrophic Factor
Author Affiliations & Notes
  • M. Hirabayashi
    Bioengineering Institute, Nidek Co Ltd, Gamagori, Japan
  • M. Nakatani
    Bioengineering Institute, Nidek Co Ltd, Gamagori, Japan
  • Y. Shinohara
    Bioengineering Institute, Nidek Co Ltd, Gamagori, Japan
  • H. Mori
    Bioengineering Institute, Nidek Co Ltd, Gamagori, Japan
  • N. Asai
    Bioengineering Institute, Nidek Co Ltd, Gamagori, Japan
  • S. Nishimura
    Bioengineering Institute, Nidek Co Ltd, Gamagori, Japan
  • Footnotes
    Commercial Relationships  M. Hirabayashi, Nidek Co.,Ltd., E; M. Nakatani, Nidek Co.,Ltd., E; Y. Shinohara, Nidek Co.,Ltd., E; H. Mori, Nidek Co.,Ltd., E; N. Asai, Nidek Co.,Ltd., E; S. Nishimura, Nidek Co.,Ltd., E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3724. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Hirabayashi, M. Nakatani, Y. Shinohara, H. Mori, N. Asai, S. Nishimura; Culture of Rat Müller Cells in Alginate Capsules for Sustained Release of Brain-Derived Neurotrophic Factor. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3724.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The brain-derived neurotrophic factor (BDNF), among other neurotrophic factors, is known for its preventive effect against retinal degeneration. We have previously reported that the immortalized rat Müller cell line, TR-MUL, act protectively on rat retinal ganglion cells through the secretion of humoral factors (ARVO 2009). In this study, we modified the TR-MUL for stable expression of BDNF and attempted to encapsulate the modified cells with future in-vivo manipulation in view.

Methods: : To obtain a cell line that stably expresses BDNF (the BD-TM4 cell line), TR-MUL cells were transfected with a plasmid that contains the BDNF gene. The BD-TM4 cells were encapsulated in 0.5% alginate at a density of 50,000 cells/capsule. Dehydrogenase activity in encapsulated cells and BDNF levels released from the capsules were quantified at days 3, 7, 14, and 21 after encapsulation by WST-8 assay and ELISA respectively. Immunostaining for glutamine synthetase (GS), a marker for the Müller cell, was performed to evaluate cell functionality.

Results: : The encapsulated Müller cells, which initially appeared as round-shaped and isolated, gradually started to aggregate to form inhomogeneous regions. Dehydrogenase activity in encapsulated cells was significantly higher at day 21 than at day 3. The capsules continuously secreted BDNF throughout 21 days at the range of 3.8-2.5 pg/day/capsule. The cells had remained immunoreactive for GS at day 21.

Conclusions: : These results demonstrate that alginate-encapsulated BDNF-secreting Müller cells maintain its viability and functionality at least for 21days.

Keywords: Muller cells • growth factors/growth factor receptors • retinal culture 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×